GlassScriptPhysician profile
Gary T Verazin
NPI 1164480968
$1,212.16
in general payments reported to CMS, 2019-2025
16 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $56.22 · 2021: $128 · 2022: $263 · 2023: $79.91 · 2024: $208 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.07 | 2019-2025 | Synthroid, Strattice Reconstructive Tissue Matrix Bps |
| Merck Sharp & Dohme LLC | $326.42 | 2019-2024 | Keytruda |
| Allergan, INC. | $86.34 | 2019-2022 | |
| Ethicon US, LLC | $83.62 | 2022 | |
| Integra Lifesciences Corporation | $31.38 | 2022 | |
| Tactile Systems Technology INC | $31.22 | 2020-2025 | Flexitouch Plus, Nimbl |
| Kowa Pharmaceuticals America, INC. | $28.91 | 2022 | |
| Myriad Genetic Laboratories, INC. | $28.27 | 2022-2024 | Myrisk |
| Ambu INC. | $21.18 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.87 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.78 | 2019 | |
| Heron Therapeutics, INC. | $13.62 | 2021 | |
| Davol INC. | $11.38 | 2019 | |
| Kci USA, INC. | $11.06 | 2020 | |
| Baxter Healthcare | $11.02 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acell, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Verazin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.